Clinical trial IMC-R117C-1004 - PIWIL1
A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC(r) Bispecific Protein) as a Single Agent and in Combination in HLA-A*02:01-Positive Participants with Selected Advanced PIWIL1-Positive Cancers (IMC-R117C-1004)
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/2 |
| Academic trial | Non |
| Sponsor | Immunocore Limited |
| EudraCT Identifier | 2023-508090-87-00 |
| Last update |